Onkologie. 2021:15(2):50-53 | DOI: 10.36290/xon.2021.009

Metastatic salivary gland cancer

Dagmar Brančíková
Interní hematologická a onkologická klinika, Fakultní nemocnice Brno

Salivary gland tumors are rare but aggressive malignancies, with increasing incidence. We present a literature review of new knowledge about the possibilities of using predictive and prognostic markers to more accurately target treatment in case of dissemination. HER2 / neu, androgen receptor and NTRK fusions are suitable tests before starting treatment of metastatic salivary gland carcinoma. Chemotherapy may be considered in a group of patients with negative results, the best data are now recently with eribulin monotherapy. Other options are tyrosine kinase inhibitors such as lenvatinib and axitinib, but there is relatively high toxicity. Salivary gland tumors are a suitable group for genomic sequencing and using a precision medicine.

Keywords: salivary gland tumors, HER2/neu, androgen receptor, NTRK fusion, NGS sequencing.

Published: April 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brančíková D. Metastatic salivary gland cancer. Onkologie. 2021;15(2):50-53. doi: 10.36290/xon.2021.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Young A, Okuyemi OT. Malignant Salivary Gland Tumors. [Updated 2020 Oct 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Go to original source...
    2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 0: 1-41. Go to original source... Go to PubMed...
    3. Lu CH, Liu CT, Chang PH, Yeh KY, Hung CY, Li SH, Lin YC, Yeh TS, Hung YS, Chou WC. Validation and Comparison of the 7th Edition of the American Joint Committee on Cancer Staging System and Other Prognostic Mo. J Cancer 2016; 7(13): 1833-1841. doi:10.7150/jca.15692. Go to original source... Go to PubMed...
    4. Lin, Her and Limesand, Kirsten and Ann, David. Current State of Knowledge on Salivary Gland Cancers. Crit Rev Oncog. 2018; 23(3-4): 139-151. doi: 10.1615/CritRevOncog.2018027598. Go to original source... Go to PubMed...
    5. Pan SY, de Groh M, Morrison H. A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada. Journal of cancer epidemiology 2017; 4909214. https://doi.org/10.1155/2017/4909214. Go to original source... Go to PubMed...
    6. Radoï L, Barul C, Menvielle G, Carton M, Matrat M, Sanchez M, Pilorget C, Velten M, Stücker I, Luce D. ICARE Study Group. Risk factors for salivary gland cancers in France: Results from a case-control study, the ICARE study. Oral Oncol. 2018; 80: 56-63. Go to original source... Go to PubMed...
    7. Mimica X, McGill M, Hay A, Karassawa Zanoni D, Shah JP, Wong RJ, Ho A, Cohen MA, Patel SG, Ganly I. Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. Cancer 126: 2153-2162. Go to original source... Go to PubMed...
    8. Mimica X, McGill M, Hay A, Karassawa Zanoni D, Shah JP, Wong RJ, Ho A, Cohen MA, Patel SG, Ganly I. Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. Cancer 2020; 126(10): 2153-2162. doi: 10.1002/cncr.32792. Epub 2020. Go to original source... Go to PubMed...
    9. Glazer TA, Shuman AG. Distant Metastases and Palliative Care. Adv Otorhinolaryngol. 2016; 78: 182-188. Go to original source... Go to PubMed...
    10. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010; 74(2): 134-148. Go to original source... Go to PubMed...
    11. Mimica X, McGill M, Hay A, Karassawa Zanoni D, Shah JP, Wong, RJ, Ho A, Cohen MA, Patel SG, Ganly I. Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. Cancer 126: 2153-2162. Go to original source... Go to PubMed...
    12. Son E, Panwar A, Mosher ChH, Lydiatt D. Cancers of the Major Salivary Gland. Journal of Oncology Practice 2018; 14:(2): 99-108. Go to original source... Go to PubMed...
    13. Skalova A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010; 34: 599. Go to original source... Go to PubMed...
    14. Witte HM, Gebauer N, Lappöhn D, et al. Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate Ca. Cancers (Basel). 2020; 12(4): 873. doi: 10.3390/cancers12040873. Go to original source... Go to PubMed...
    15. Hang H, Kim JS, Choi YJ, Cho J-G, Woo J-S, Kim A, et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. OncoTargets Ther 2017; 10: 2983-2992. Go to original source... Go to PubMed...
    16. Lin FChF, Chen Pl, Tsao TY, Li CR, Jeng KC, Tsai SCS. Prevalence of human papillomavirus and Epstein-Barr virus in salivary gland diseases. The Journal of International Medical Research 2014; 42(5): 1093-1101. Go to original source... Go to PubMed...
    17. Hintakuntlawar AV, Okuno SH, Price KA. Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers Head Neck 2016; 11: 1. Go to original source...
    18. Minichsdorfer C. Systemic therapy for metastatic salivary gland tumors - challenges and novel concepts. 2020; 13: 400-404. Go to original source...
    19. Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head & Neck 2018; 40: 605- 613. Go to original source... Go to PubMed...
    20. Boxtel van W, Locati LD, et al. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. European Journal of Cancer 2019; 110: 62-70. Go to original source... Go to PubMed...
    21. Xu B. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance Human Pathology 2019; 93: 30-36. Go to original source... Go to PubMed...
    22. Ho AL, et al. Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers. Journal of Clinical Oncology 2019; 37(Suppl. 15): 6020-6020. Go to original source...
    23. Clauditz TS, Reiff M, Gravert L, et al. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology 2011; 43: 459-464. Go to original source... Go to PubMed...
    24. Skálová A, Stárek I, Kučerová V. Salivary Duct Carcinoma - A Highly Aggressive Salivary Gland Tumor with HER-2/neu Oncoprotein Overexpression. Pathology - Research and Practice 2001; 197(9): 621-626. Go to original source... Go to PubMed...
    25. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T. Clinical and immunohistologic typing of salivary duct carcinoma. Cancer 2005; 103: 2526-2533. Go to original source... Go to PubMed...
    26. Takahashi H, et al. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. Journal of Clinical Oncology 2019; 37(2): 125-134. Go to original source... Go to PubMed...
    27. Boxtel van W. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. Oral Oncol. 2017; 72: 198-200. Go to original source... Go to PubMed...
    28. Corrêa TS, et al. Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab. Case Rep Oncol 2018; 11: 252-257. Go to original source... Go to PubMed...
    29. Sorenson KR, Piovezani Ramos G, Villasboas Bisneto JC, Price K. Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib. Case Rep Oncol 2017; 10: 726-731. Go to original source... Go to PubMed...
    30. Vidal L, et al. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 2009; 31: 1006-1012. Go to original source... Go to PubMed...
    31. Hanna GJ, et al. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers Oncologist 2020; 25(7): 598-608. doi: 10.1634/theonc. Go to original source... Go to PubMed...
    32. KIcati, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncology. July 2009; 45(7): 574-578. Go to original source... Go to PubMed...
    33. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR, Jr. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck 2015; 37: 644-649. Go to original source... Go to PubMed...
    34. Di Villeneuve L, Souza IL, Tolentino FDS, Ferrarotto R, Schvartsman G. Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. Front Oncol. 2020; 10: 580141. doi: 10.3389/fonc.2020.580141. PMID: 33194707; PMCID: PMC7649804. Go to original source... Go to PubMed...
    35. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005; 23(3): 585-90. doi: 10.1200/JCO.2005.06.125. PMID: 15659505. Go to original source... Go to PubMed...
    36. Chintakuntlawar AV, Okuno SH, Price KA. Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers Head Neck 2016; 1: 11. https://doi.org/10.1186/s41199-016-0011-z. Go to original source... Go to PubMed...
    37. Tchekmedyian V, et al. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; 37(18): 1529. Go to original source... Go to PubMed...
    38. Locati LD, Cavalieri S, Bergamini C, et al. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head & Neck 2019; 41: 3670-3676. Go to original source... Go to PubMed...
    39. Hung YP, Jo VY, Hornick JL. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma. Histopathology 2019; 75: 54- 62. https://doi.org/10.1111/his.13845. Go to original source... Go to PubMed...
    40. Rooper LM, Karantanos T, Ning Y, Bishop JA, Gordon SW, Kang H. Salivary secretory carcinoma with a novel ETV6-MET fusion expanding the molecular spectrum of a recently described entity. Am J Surg Pathol 2018; 42: 1121-1126. Go to original source... Go to PubMed...
    41. Drilon A, Laetsch T, Kummar S, DuBois S, Lassen U, Demetri G, et al. Efficacy of larotrectinib in TRK fusion- positive cancers in adults and children. N Engl J Med. 2018; 378: 731-739. Go to original source... Go to PubMed...
    42. Doebele R, Drilon A, Paz-Ares L, Siena S, Shaw A, Farago A, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet 2020; 21: 271-82.Literatura u autorky a na www.onkologiecs.cz Go to original source... Go to PubMed...
    43. Hyman D, Kummar S, Farago A, Geoerger B, Mau-Sorensen M, Taylor M, et al. CT-127 - phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) [abstract]. In: Proceedings of the 10th Annual Meeting of.
    44. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31(11): 1491-1505. doi: 10.1016/j.annonc.2020.07.014. Epub 2020 Aug 24. PMID: 32853681. Go to original source... Go to PubMed...
    45. Brančíková D. Novinky v léčbě nádorů slinných žláz. Head and Neck Cancer 2019; 1: 4.
    46. Lagha AC. Systemic therapy in the management of metastatic or advanced Systemic therapy in the management of salivary gland cancers. Head & Neck Oncology 2012; 4: 19. Go to original source... Go to PubMed...
    47. Keith DE. Phase II trial of eribulin for recurrent or metastatic salivary glandcancers. Journal of Clinical Oncology 2016; 34(Suppl. 15): 6095-6095. Go to original source...
    48. Gilbert J, Cmelak A, Shyr Y, Netterville J, Burkey BB, Sinard RJ, et al. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer 2008; 113: 186-192. Go to original source... Go to PubMed...
    49. Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S, Bumma C. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001; 91: 54. Go to original source...
    50. Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. Am J Clin Oncol. 2018; 41(11): 1083-1088. doi: 10.1097/COC.0000000000000429. PMID: 29462123; PMCID: PMC6211783. Go to original source... Go to PubMed...
    51. Tchekmedyian V, Sherman EJ, Dunn L, Fetten JV, Michel LS, Kriplani A, et al. A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). J Clin Oncol 2019; 37: 6084. Go to original source...
    52. Jerome F, et al. NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. Journal of Clinical Oncology 2019; 37(Suppl. 15): 6083-6083. Go to original source...
    53. Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020; 31(3): 412-421. doi: 10.1016/j.annonc.2019.11.018. Epub 2019 Dec 9. PMID: 32067683. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.